Overview

Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
A prospective, open-label, single-arm clinical study of mitoxantrone hydrochloride liposome injection combined with daratumumab and dexamethasone in the treatment of relapsed/refractory multiple myeloma
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital of Soochow University
Collaborator:
The Affiliated Hospital of Xuzhou Medical University
Treatments:
Daratumumab
Dexamethasone
Mitoxantrone